NEW YORK (GenomeWeb) – Qiagen has extended the offer period for its DKK683 million ($103.5 million) acquisition of Exiqon. It announced in late March a voluntary conditional public takeover offer to buy all of Exiqon's shares for DKK18 per share, and as of the end of the day on May 18 had received acceptances from shareholders in Exiqon representing around 81 percent of the share capital and voting rights in the firm. Qiagen said the offer now expires at the end of the day on June 2.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.